Austin Px

Attendee interviews from the ASD Workshop in Austin, TX held by Austin Px

Collaboration and Innovation are at the Heart of AustinPx’s ASD Workshop

In this series of interviews conducted at AustinPx’s second biannual Amorphous Solid Dispersions (ASD) Workshop, attendees share their key takeaways and hopes for the future of the industry. They discuss solubility, supersaturation, drug product development, and the collaborative energy fueling innovation in ASD technologies. While technical challenges persist, the shared commitment to advancing amorphous pharmaceutical science continues to shape the future of this critical industry sector.

Videos

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.

Articles

The management of lung cancer brain metastases has seen significant advancements, with a focus on personalized treatment strategies. The integration of targeted therapies and immunotherapies has improved patient outcomes, offering more effective and less invasive options compared to traditional methods. Stereotactic radiosurgery and whole-brain radiation therapy remain crucial, but their roles are evolving with the advent of novel systemic treatments. Multidisciplinary approaches are essential for optimizing care, emphasizing the importance of collaboration among oncologists, neurosurgeons, and radiation specialists to tailor interventions based on individual patient profiles and tumor characteristics.

As molecules grow more complex, drug developers in the pharma landscape face an increasing number of challenges in formulation, manufacturability, and sustainability. Fortunately, novel formulation strategies and technologies are reshaping drug development, from overcoming oral solid dose (OSD) challenges to advancing bioavailability and redefining traditional drug-likeness criteria. 

Pushing the Boundaries: Overcoming Formulation and Manufacturing Challenges in Today's Pharmaceutical Development Landscape 

The KinetiSol® Technology: Disrupting the Solid Amorphous Dispersion Landscape

to provide an overview of AustinPx, the company's bioavailability offerings, and KinetiSol technology, which represents a major breakthrough in amorphous dispersions. Learn more about:

How AustinPx was created and the strategy behind taking a technology company and turning it into a CDMO;

The origin of KinetiSol and how it can provide a faster, broader, and greener technology for amorphous solid dispersions;

How KinetiSol can alleviate challenges associated with spray drying.

Elizabeth Hickman (Chief Business Officer, AustinPx) explains the company's approach to improving bioavailability, highlighting KinetiSol technology.